West Pharmaceutical Revised FY23 Sales Guidance To $2.950B-$2.960B From $2.97B-$2.995B, Vs. Consensus Of $2.99B, Adjusted EPS To $7.95 to $8.00 From $7.65-$7.80 Vs. Consensus Of $7.85
Portfolio Pulse from Benzinga Newsdesk
West Pharmaceutical has revised its FY23 sales guidance to $2.950B-$2.960B from $2.97B-$2.995B, which is below the consensus of $2.99B. The company also adjusted its EPS to $7.95 to $8.00 from $7.65-$7.80, which is above the consensus of $7.85. The Q4 2023 EPS guidance assumes a 22% tax rate and does not include potential tax benefits from stock-based compensation.
October 26, 2023 | 10:21 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
West Pharmaceutical's revised FY23 sales guidance is below the consensus, which could negatively impact the stock. However, the adjusted EPS is above the consensus, which could have a positive effect.
The company's revised sales guidance is below the market consensus, which could lead to a negative sentiment among investors and potentially a drop in the stock price. However, the adjusted EPS is above the consensus, which could offset the negative impact and potentially lead to a rise in the stock price. The net effect is uncertain, hence a neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100